Inovio Pharmaceuticals Inc (INO)

[Opus X]

More biotech mergers and acquisitions

There is a good case for it, though. “Big pharma has so much cash they could basically buy the whole midcap universe,” notes Yee. Their cumulative cash balance has now risen to more than $300B “The CFOs of big pharma are looking at this carnage, and they are just licking their chops,” says McDonald. “You are probably going to see substantially more transactions down here.”